Description:
The current state of Art
Triggering ovulation is a crucial step in the management of the controlled ovarian stimulation in patients undergoing IVF, IUI, timed intercourse and other forms of fertility therapy. Currently, human chorionic gonadotrophin (hCG), is the only FDA-approved medication to trigger ovulation.
The problems with the current art
But hCG can cause a high incidence of ovarian hyperstimulation syndrome; in serious cases, patients can experience blood clots, shortness of breath, abdominal pain, dehydration, and even death. Although other therapies are being investigated to trigger ovulation, they do not reproduce naturally occurring pulsating patterns of GnRH and are expensive.
The advantages of our invention:
The current invention is to administer one-time progesterone to induce ovulation at the end of the follicular phase to induce LH and FSH surge and to trigger ovulation. It has been shown that progesterone injection can induce LH surge, trigger the follicle rupture, and release of the oocytes in 3 patients. In addition, progesterone has been used to support the luteal phase to ensure a successful pregnancy. Thus the use of progesterone to trigger ovulation can help patients avoid additional painful daily progesterone injections. At last, the progesterone is safe, inexpensive and well-tolerated. Therefore, the use of progesterone can be a promising and effective medication to trigger ovulation in infertility management.
AURI # 2020-022
IP status: PCT/US20/28121